Premature Ejaculation Treatment Market 2024-2028: Size and Side effects associated with premature ejaculation treatment drugs; growth driven by the Route Of Administration, Some of key Companies Positioned Strategically

The premature ejaculation treatment market size by Route Of Administration (Oral and Topical), Drug Class (SSRIs, PDE5 inhibitors, Amide anesthetics, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1459.85 million. The market is expected to grow at a CAGR of   8.78% between 2024 and 2028.

• The premature ejaculation treatment market encompasses various off-label medications, primarily Phosphodiesterase-5 (PDE5) inhibitors. While these drugs offer relief for some, they carry significant side effects that may hinder their adoption. Notable adverse reactions include prolonged erections lasting over four hours, a condition termed priapism, and painful erections persisting beyond six hours. These risks necessitate careful consideration and potential alternative treatment options.
• The North American region holds a dominant position in the global premature ejaculation (PE) treatment market, driven by a substantial increase in PE cases due to psychological stress and lifestyle changes. PE is a prevalent sexual disorder among men under 40 years old, making the US market particularly significant. Leading industry players, such as Innovus Pharmaceuticals and Absorption Pharmaceuticals, are based in North America and are actively participating in the market. Innovus Pharmaceuticals has already introduced PE drugs like EjectDelay, while Absorption Pharmaceuticals' FORTACIN (PSD502 or Tempe spray) is pending US FDA approval for launch.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• A. Menarini Industrie Farmaceutiche Riunite Srl
• Absorption Pharmaceuticals LLC
• Alembic Pharmaceuticals Ltd.
• Amneal Pharmaceuticals Inc.
• Aytu BioPharma Inc.
• Bayer AG
• Eli Lilly and Co.
• Futura Medical plc
• GlaxoSmithKline Plc
• Johnson and Johnson
• LloydsPharmacy
• Morari Inc.
• NeuroHealing Pharmaceuticals Inc.
• Niksan Pharmaceutical
• Pfizer Inc.
• Plethora Solutions Ltd.
• Prinston Pharmaceutical Inc.
• Ralington Pharma LLP
• Sunrise Remedies Pvt. Ltd.
• Tabuk Pharmaceuticals
• Veru Inc.
• VIVUS LLC

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/